Radspherin Opportunity The merged entity Oncoinvent ASA is actively advancing Radspherin, an alpha radiation therapy for abdominal cavity cancers, with ongoing phase 2 recruitment in Norway and internationally. This presents a sales opportunity for radiopharmaceutical facilities, off-the-shelf alpha radiation supply, and contract research organizations supporting alpha therapy manufacturing, distribution, and regulatory support.

Clinical Collaboration Partnership potential exists with ARTBIO for radiopharma laboratory facilities and ongoing collaboration opportunities, enabling access to specialized radiopharma production capabilities, regulatory consulting, and shared clinical trial infrastructure to accelerate development timelines.

Strategic Merger The merger combines BerGenBio’s oncology focus with Oncoinvent’s radiopharma platform, widening the product and services portfolio. This creates cross-sell opportunities for cell signaling and targeted therapy expertise to radiopharma programs, while leveraging a broader investor and pharma validation profile.

Global Trials Phase 2 trials are being conducted both in Norway and internationally, signaling a need for global trial support services, site networks, regulatory submissions across regions, and patient recruitment strategies that can be offered by contract research and clinical operations partners.

Financial Quiet Strength With funding of $183M and a revenue footprint under $1M, there is a market need for cost-effective manufacturing, supply chain services, and CMOs experienced in radiopharmaceuticals to scale production, reduce costs, and optimize cash burn as the company scales its alpha therapy platform.